The purpose of this study is to assess the safety and effectiveness of an investigational injection medication (active study drug) compared to placebo (inactive substance) in the treatment of moderate-to-severe eczema.
Men and women who have had a diagnosis of atopic dermatitis for at least 2 years and are aged 12 and older may qualify to receive study drug at no cost. There is no cost to participate, and participants will receive compensation for travel related expenses.
In order to qualify, participants must have at least 10% of their body surface area covered in eczema, excluding their palms, soles, and scalp. This is equivalent to 10 palm sized patches, including fingers.
Participants will be asked to visit the study centre about 11 times and participate in one phone call visit over a period of about 65 weeks.
Email Tina Craig, Clinical Research Coordinator at DermEffects to register.